Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL...

Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA

PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel ( Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA )

Researchers trace the origin of blood cancer to early childhood, decades before...

Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK

Researchers trace the origin of blood cancer to early childhood, decades before diagnosis ( Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK )

Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

$Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by measuring circulating tumour DNA ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )$

ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr...

$ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma ( Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith )$

Survival analysis of newly diagnosed transplant-eligible multiple myeloma...

Dr Francesca Gay - University of Torino, Torino, Italy

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial ( Dr Francesca Gay - University of Torino, Torino, Italy )

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with...

Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ( Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy )

FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Clinical activity and safety of cevostamab in relapsed/refractory multiple...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

$Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )$

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia

Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia ( Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany )

ASCENT: A phase II trial of induction, consolidation and maintenance in...

Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM ( Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA )

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic...

Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht...

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study ( Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )

More from ecancer